Clinical Trial Update: A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor [Phase 1, Phase 2]

View source ↗

Summary

A safety, tolerability, PK and preliminary activity study of GB263T in advanced NSCLC and other solid tumors is in Phase 1/Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GB263T

Snippet

Sponsor: Genor Biopharma Co., Ltd. | Conditions: NSCLC, Other Solid Tumors | Phase 1, Phase 2 | Status: UNKNOWN